GeneDx Holdings (WGS) shares surged 26.02% to $107.00 in pre-market trading on Tuesday, July 29, 2025, up from the previous close of $84.91.
The rally was driven by strong Q2 2025 results: adjusted EPS of $0.50 beat estimates by 400% and reversed a year-ago loss, while revenue of $102.69 million topped forecasts by nearly 20% and rose 45.6% year-over-year.
The company also raised its full-year revenue guidance to $400–$415 million, well above consensus estimates.
